Published online Nov 16, 2015. doi: 10.12998/wjcc.v3.i11.935
Peer-review started: August 26, 2014
First decision: September 28, 2014
Revised: July 28, 2015
Accepted: August 4, 2015
Article in press: August 7, 2015
Published online: November 16, 2015
Core tip: Current clinical guidelines seldom include cost-effectiveness evaluations. Conclusions are typically based on clinical data only and sometimes referral is made to prices of therapies for justification of the treatment sequence advised. However, the price of a therapy as such is just a single criterion and does not reflect the balance between effectiveness and costs associated with the application of that therapy. This results often in a restricted position of new therapies in the treatment algorithm. Integration of cost-effectiveness using the population-based variant of cost-effectiveness evaluations as an instrument in guidelines for Clostridium difficile infection may be provide better decision making framework.